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ABSTRACT
Purpose Fourth-generation poly(propylene imine)
dendrimers fully surface-modified by maltose (dense shell,
PPI-m DS) were shown to be biocompatible in cellular
models, which is important for their application in drug deliv-
ery. We decided to verify also their inherent bioactivity, in-
cluding immunomodulatory activity, for potential clinical ap-
plications.We tested their effects on the THP-1monocytic cell
line model of innate immunity effectors.
Methods To estimate the cytotoxicity of dendrimers the
reasazurin assay was performed. The expression level of
NF-κB targets: IGFBP3, TNFAIP3 and TNF was determined by
quantitative real-time RT-PCR. Measurement of NF-κB p65
translocation from cytoplasm to nucleus was conducted with a
high-content screening platform and binding of NF-κB to a
consensus DNA probe was determined by electrophoretic mo-
bility shift assay. The cytokine assay was performed to mea-
sure protein concentration of TNFalpha and IL-4.
Results We found that PPI-m DS did not impact THP-1
viability and growth even at high concentrations (up to
100 μM). They also did not induce expression of genes for
important signaling pathways: Jak/STAT, Keap1/Nrf2 and
ER stress. However, high concentrations of 4th generation
PPI-m DS (25–100 μM), but not their 3rd generation coun-
terparts, induced nuclear translocation of p65 NF-κB protein
and its DNA-binding activity, leading to NF-κB-dependent
increased expression of mRNA for NF-κB targets: IGFBP3,
TNFAIP3 and TNF . However, no increase in pro-
inflammatory cytokine secretion was detected.
Conclusion We conclude that maltose-modified PPI
dendrimers of specific size could exert a modest immunomod-
ulatory effect, which may be advantageous in clinical applica-
tions (e.g. adjuvant effect in anti-cancer vaccines).
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ABBREVIATIONS
BSA Bovine serum albumin
CHOP DNA damage inducible transcript 3
DTT Dithiothreitol
EDEM ER degradation enhancing
alpha-mannosidase like protein 1
ELISA Enzyme-linked
immunosorbent assay
EMSA Electrophoretic mobility shift assay
HPRT1 Hypoxanthine phosphoribosyltransferase 1
IGFBP3 Insulin-like growth factor-binding protein 3
IL-4 Interleukin 4
IRDye 700 Infrared fluorescent dye, 700 nm
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Jak/STAT Janus kinase/Signal transducers and
activators of transcription
Keap1/Nrf2 Monoacidic inhibitors of the kelch-like
ECH-associated protein 1/Nuclear factor
erythroid 2-related factor 2
MBL Mannan-binding protein
NF-κB Nuclear factor kappa-light-chain-enhancer
of activated B cells
OSM Oncostatin-M
PAMAM Poly(amidoamine) dendrimers
PEI Poly(ethylene imine) dendrimers
PPI-m DS G3 Dense shell maltose-modified
3rd generation poly(propylene imine)
glycodendrimers
PPI-m DS G4 Dense shell maltose-modified
4th generation poly(propylene imine)
glycodendrimers
PRDX1 Peroxiredoxin 1
RT-PCR Real time polymerase chain reaction
SOCS3 Suppressor of cytokine signaling 3
SOD2 Superoxide dismutase 2, mitochondrial
TBP TATA box binding protein
THP-1 Human monocytic cell line
TNF Tumor necrosis factor
TNFAIP3 Tumour necrosis factor alpha-induced
protein 3
INTRODUCTION
Since the early 1980s, dendrimers have been comprehen-
sively studied for various medical applications (1). These
highly branched macromolecules offer many advantages
when compared to other chemical polymers with different
architectural forms (2). Thanks to the development of pre-
cise methods of synthesis it became possible to obtain
homogeneous compounds with specified chemical features
and well-defined structure. This includes a central core
with radially attached polymeric branches and peripheral
functional groups (3). All those elements affect the size
and shape of the dendrimer, at the same time providing
a number of unique properties (4). Dendrimers are used
both in drug delivery and as bona fide bioactive com-
pounds, however it is important to distinguish the chem-
ical and biochemical characteristics that make them suit-
able for these goals.
The biological features of dendrimers, such as high
solubility and biopermeability, are affected by the charac-
ter of highly-reactive terminal moieties (5). Unfortunately,
in some polyamine dendrimer types, e.g. poly(propylene
imine) (PPI) dendrimers, the properties of the dendritic
scaffold are too harsh, making them bio-incompatible
for direct application. Therefore, intensive research is be-
ing performed on properties of dendrimers with diverse
end group modifications. Because of non-specific interac-
tions with negatively-charged biological membranes, cat-
ionic dendritic polymers, such as poly(amidoamine)
(PAMAM) or poly(propylene imine) (PPI) dendrimers,
are more hemolytic and cytotoxic (6,7) in comparison to
neutral and anionic macromolecules (8). A positive surface
charge significantly limits the medical applicability of this
type of dendrimers. Therefore, it is important to find the
right balance between toxic side effects and unique prop-
erties allowing the therapeutic application of dendrimers.
The reduction of toxicity of positively charged macromol-
ecules is possible through chemical modifications of ter-
minal groups. For this purpose, poly(ethylene glycol)
chains have been most commonly studied (9), as well as
fatty acids (7), and acetyl or glycidol groups (6). In addi-
tion, certain surface modifications have been found to
improve the targeting potential, biocompatibility and
biodistribution of dendrimers (10,11).
In order to develop efficient drug delivery system, scientific
interest turned to glycodendrimers (7,12,13). Modification
with sugar moieties has been found to significantly lower the
cytotoxic activity of dendrimers, as well as prolong their blood
half-life, improve biocompatibility and loading capacity
(12–14). Carbohydrates may also enhance the molecular
recognition potential of glycodendrimers thanks to the specific
interactions with lectin receptors overexpressed on various
types of cancer cells (15).
Maltose-coated PPI dendrimers have shown a very good
combination of biocompatibility and bioactivity (12,13).
While fully surface-modified PPI-m glycodendrimers are
unsuitable as drug delivery vehicles for anionic drug mol-
ecules (16), they have unique bioactivities that are just
starting to be characterised. Our research concentrates
on validating potential applications of maltose-modified
glycodendrimers due to their specific interactions with
biological systems, including immune recognition path-
ways. Immunomodulation is a very important goal in
nanopharmacology, because specific and targeted activa-
tion or inhibition of immune cell proliferation, antibody
secretion or cytokine release would be preferable to cur-
rently available broad-target chemical immunomodulators
which have severe side effects (17). Since oligosaccharide
end groups are very important in immune recognition, we
set out to test the potential immunomodulatory potency of
PPI-m glycodendrimers, as exemplified by signaling path-
ways in the THP-1 cell line as monocyte model.




Poly(propylene imine) dendrimer of the 4th generation
with primary amino surface groups was obtained from
Symo-Chem (Eindhoven; Netherlands) and modified
with maltose to 90% extent (dense shell glycodendrimers;
PPI-m DS G3, MW 24,397 g/mol or PPI-m DS G4,
MW 44,500 g/mol) (Scheme 1). Dendrimers were syn-
thesized, purified and characterized as previously de-
scr ibed (18) . The molecular weight of the PPI




THP-1 (acute monocytic leukemia) human cell line was pur-
chased from ATCC (Manassas, VA, USA) and maintained
under standard conditions in RPMI-1640 Medium
(ThermoFisher) supplemented with 10% fetal bovine serum
(Sigma-Aldrich) at 37°C in an atmosphere of 5% CO2. Cells
were sub-cultured three times per week.
Cytotoxicity Assay
To estimate the potential cytotoxicity of dendrimers resazurin
assay was performed (20) to investigate cells. Cells were seeded





















































































































































































































































Scheme 1 The structure of PPI
dendrimer of the 4th generation
modified with maltose
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and treated with increasing concentrations of dendrimers for
24 and 72 h. Following the incubation, resazurin was added to
the culture medium to a final concentration of 10 μg/ml and
the plates were incubated at 37°C in darkness to allow con-
version of resazurin to resorufin. Fluorescence of metabolized
resazurin in the cell suspension was measured after 30 and
90 min at 530 nm excitation and 590 nm emission using
EnVision plate reader (PerkinElmer, Waltham, USA). Cell
viability was calculated as the increase in resorufin fluores-
cence between 30 and 90 min and was presented as percent-
age of untreated control.
Gene Expression Assay
The expression level of NF-κB marker genes (IGFBP3,
TNFAIP3) or cytokine genes (TNF, IL-4) was determined by
quantitative real-time RT-PCR. Aliquots of 1 × 106 of THP-1
cells were cultured for 24 h with the PPI-m DS G4 (or PPI-m
DS G3) glycodendrimer. In some experiments, cells were co-
incubated with parthenolide (Sigma-Aldrich) as a pharmaco-
logical inhibitor of the NF-κB pathway. Following incubation,
cells were harvested, washed once with PBS and processed for
mRNA us ing Dynabead s mRNA DIRECT Ki t
(ThermoFisher) according to manufacturer’s protocol for cul-
tured cells. Complementary DNA (cDNA) was then tran-
scribed from mRNA via High Capacity cDNA Reverse
Transcription Kit (ThermoFisher). It was subsequently used
for real-time PCR amplification using the Express SYBR
GreenER qPCR SuperMix Universal (ThermoFisher) ac-
cording to manufacturer’s protocol. Each 10 μl reaction vol-
ume contained 1 μl of cDNA and 0.4 μM of forward and
reverse primers. PCR reactions were performed in 96-well
microplates using the CFX96 Real Time PCR Detection
System (Bio-Rad). The following intron-spanning gene-
specific primers were used: IGFBP3 REV (5′-AGCT
CCAGGAAATGCTAGTGAGTC-3′); IGFBP3 FOR (5′-
GGTGGAACTTGGGATCAGACAC-3′); TNFAIP3 REV
(5 ′ -CTTGACCAGGACTTGGGACTTTGC-3 ′ ) ;
TNFAIP3 FOR (5′-AGCCATTGTGCTCTCCAACA
CCTC-3 ′ ) ; TNF REV (5 ′ -ATCTCTCAGCTCCA
CGCCATTG-3′); TNF FOR (5′-CCAGGCAGTCAGAT
C A TC TT C TCG - 3 ′ ) ; I L 4 R E V ( 5 ′ - T C T C
ATGGTGGCTGTAGAACTGC-3 ′ ) ; IL4 FOR (5 ′-
ACAGCCTCACAGAGCAGAAGAC-3′); as well as primers
specific for housekeeping HPRT1 and TBP genes: HPRT1
FOR (5′-TGACACTGGCAAAACAATGCA-3′); HPRT1
REV (5′-GGTCCTTTTCACCAGCAAGCT-3′); TBP
FOR (5′-CACGAACCACGGCACTGATT-3′); TBP REV
(5′-TTTTCTTGCTGCCAGTCTGGAC-3′). The above
reference genes were selected previously for the cell/treatment
combination according to the GeNorm procedure (21). The
expression level of assayed genes was calculated by the ΔΔCt
method as the number of cognate mRNA copies per 1 copy of
geometric-averaged mRNA for reference genes.
NF-κB Translocation Assay
Cultured THP-1 cells were stimulated for 2.5 h with the PPI-
m DS G4 glycodendrimer or with TNFα as a positive control.
Aliquots of 5 × 104 cells were then withdrawn from the culture
and transferred to a thin-bottom 96-well plate coated previ-
ously with poly-lysine. After 10 min of sedimentation at 37°C,
cells were centrifuged (5 min, 100×g, RT) to enhance cell
adhesion to the plate. Following gentle aspiration of culture
medium and a single wash with PBS, cells were immediately
fixed for 20 min at room temperature with PBS-buffered 2%
formaldehyde solution freshly prepared from paraformalde-
hyde. Subsequently, cells were washed once with blocking
buffer (PBS, 1% BSA, 0.1% Triton X-100) and further incu-
bated with the blocking buffer overnight at 4°C. NF-κB was
then probed for one hour with DyLight488-conjugated anti-
body diluted in the blocking buffer (anti-NF-κB p65
DyLight488 rabbit monoclonal antibody, EP2161Y, Abcam,
1:100). Finally, after three wash cycles with the blocking
buffer, nuclei were stained with 5 μM Hoechst 33342 dye for
5 min and cells were stored protected from light in PBS/
0.02% NaN3 at 4°C until imaging. Measurement of NF-κB
p65 translocation from cytoplasm to nucleus was conducted
with a high-content screening platform (ArrayScanVTi from
ThermoFisher) using manufacturer’s proprietary software
and protocol for measuring the ratio of nuclear to cytoplasmic
staining (22). Measurements were made for >2500 cells per
single well, ratios were averaged within the well and taken as
single biological replicates. Data is presented as percentage of
control (untreated) translocation ratio. The number of repli-
cates indicated in the figure refers to the number of biological
replicates of treatment experiment.
Electrophoretic Mobility Shift Assay (EMSA)
THP-1 cells (1 × 106) were harvested after 2.5 h of treatment,
washed once with PBS and centrifuged at 500×g for 3 min.
Supernatant was carefully removed, leaving the cell pellet as
dry as possible. Nuclear extracts were then prepared using the
NE-PER Nuclear and Cytoplasmic Extraction Reagents
(ThermoFisher) with the Halt Protease and Phosphatase
Inhibitor Cocktail (ThermoFisher) according to the manufac-
turer’s recommendation. Protein concentration of extracts
was determined using the Microplate BCA Protein Assay
Kit – Reducing Agent Compatible (ThermoFisher) and ali-
quots were frozen at −80°C until use.
Nuclear extracts were analyzed for the presence of active
(DNA-binding) NF-κB using double-stranded oligonucleo-
tides probes with the NF-κB consensus binding sequence, la-
beled with IRDye 700 infrared fluorescence dye (5′-AGT
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TGA GGG GAC TTT CCC AGG C-3′, consensus site is
underlined, custom-synthesized by Metabion International
AG). Extracts were incubated for 30 min at 4°C with
0.5 μg/ml salmon spermDNA in binding buffer: 5% glycerol,
10 mM MgC12, 1 mM DTT, 50 mM NaCl, 0.1% NP-40,
0.4 μM ZnCl2 and 10 mM Tris-HCI, pH 8 with or without
the addition of 2 pmol/μl of the competing, unstained oligo-
nucleotide probe. After this time, labelled NF-κB probes were
added to the mixture at the final concentration of 0.02 pmol/
μl and further incubated 30 min at 4°C. DNA-protein com-
plexes were analyzed by electrophoresis in denaturing condi-
tions on a 12% polyacrylamide gel at 4°C. The probe-protein
complexes were visualized on an Odyssey IR imager (Li-Cor).
Band intensities were quantified digitally using ImageJ
software.
Cytokine Assay
Cultured THP-1 cells were stimulated for 24 h with the PPI-m
DS G4 glycodendrimer. Subsequently, cells were removed by
centrifugation (5 min, 5000×g, RT) and protein concentration
of TNFα and IL-4 was measured in the supernatant using
Quantikine ELISA kits (R&D Systems). The assay was per-
formed strictly according to manufacturer’s protocol, the ab-
sorbance was read in an EnVision plate reader (Perkin Elmer)
at 450 nm.
Statistics
For statistical significance testing we used one-way ANOVA
for concentration series followed by post-hoc Tukey’s test for
pairwise difference testing. In all tests, p values < 0.05 were
considered to be statistically significant. Data are presented
as arithmetic mean ± S.E.M.
RESULTS
In order to test the biocompatibility of PPI-m DS
glycodendrimers with the cellular model applied in this study,
the survival rate of THP-1 cells following treatment with a
range of PPI-m DS G4 concentrations (3.125–100 μM) was
measured using the resazurin assay method. Cells were treat-
ed for 24 and 72 h and compared with untreated cells (Fig. 1),
demonstrating that at these concentrations PPI-m DS G4
glycodendrimers do not influence cell viability to any measur-
able extent even during a prolonged incubation.
Since our main goal was to identify potential novel bioac-
tivities of glycodendrimers, which might lead to immunomod-
ulatory side effects by their interference with cellular signaling
pathways, we evaluated gene expression at the mRNA level of
a set of marker genes. These genes were selected as known
targets of main cellular pathways that respond to xenobiotic
stress and contr ibute to immunomodulat ion and
immunotoxicity in myeloid cells: the Jak/STAT pathway
(SOCS3, OSM), the NF-κB pathway (TNFAIP3, IGFBP3), the
Keap1/Nrf2 pathway (PRDX1, SOD2) and the ER stress path-
way (CHOP, EDEM). In THP-1 cells treated with PPI-m DS
G4 glycodendrimers at different concentrations (25 or
100 μM) for 24 h, a statistically significant effect – activation
of mRNA expression – was detected only for the two gene
markers of the NF-κB pathway (Fig. 2a). Expression levels of
all the other marker genes remained constant after treatment
(data not shown). In the case of TNFAIP3 and IGFBP3, the
induction of expression was dose-dependent, with up to 2-fold
increase for the top concentration tested (100 μM). As a con-
trol of role of glycodendrimer size, we performed the same
experiments using a corresponding lower-generation dendri-
mer – PPI-m DS G3. At the same concentrations (25 or
100 μM), no statistically significant stimulatory effect on the
expression of NF-κB pathway could be detected (Fig. 2b).
Since activation of marker gene expression is an indirect
proof of pathway activation and may be caused by other ef-
fects, we subsequently set out to prove the direct involvement
o f the NF-κB pathway in ce l lu l a r re sponse to
glycodendrimers. Since a hallmark of NF-κB activation is
the translocation of this transcription factor from the cyto-
plasm to the nucleus, we used a high-content screening assay
to reliably and objectively quantify this translocation in
glycodendrimer-treated cells. Figure 3 shows that treatment
with PPI-m DS G4 induces NF-κB translocation in a dose-
dependent manner to an extent similar to that observed for
marker gene induction (more than 2-fold). In the same setting,
a control NF-κB-activating stimulus, TNFα treatment, was
able to induce stronger NF-κB translocation than the top
glycodendrimer concentration, indicating that the mode of
stimulation of the NF-κB pathway by PPI-m DS G4 is prob-
ably distinct from specific receptor-mediated interactions.
The function of NF-κB after translocation into the nu-
cleus depends on its ability to bind specific DNA regulatory
elements and influence the transcriptional rate. To confirm
that PPI-m DS G4 glycodendrimers can cause this effect,
we measured active nuclear NF-κB content using the elec-
trophoretic mobility shift assay (EMSA). Figure 4a shows
that PPI-m DS G4 treatment of THP-1 cells promotes
stronger binding of a nuclear protein to an NF-κB-
specific consensus oligonucleotide, demonstrated as en-
hanced intensity of a mobility-shifted band. An even stron-
ger enhancement of this band is seen with the positive
control stimulus TNFα. Another shifted band of strong
intensity appears below this band – this band is not en-
hanced either by TNFα or PPI-m DS G4 treatment. It
has been demonstrated in previous literature using the
same probe sequence that this band is due to non-NF-κB
nuclear proteins binding to the same sequence and that the
weaker upper band corresponds to actual active p65
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binding (23). For this reason, we quantified this upper spe-
cific band in biological replicate experiments by image
analysis (Fig. 4b) – the results are highly similar to those
obtained for nuclear translocation and marker gene ex-
pression, with ca. 2-fold induction by 100 μM PPI-m DS
G4.
Final confirmation of the involvement of classical NF-κB
pathway in marker gene induction by glycodendrimer treat-
ment comes from the results of application of parthenolide,
which is a known and specific pharmacological inhibitor of
this pathway, working by inhibition of I-κB kinase and/or
direct modification of the p65 protein (24). As expected, ap-
plication of 5 μM parthenolide alone caused a ca. 2-fold de-
crease in basal NF-κB marker gene expression in THP-1 cells
(Fig. 5). Significantly, concurrent application of parthenolide
prevented the induction of IGFBP3 and TNFAIP3 gene ex-
pression by PPI-m DS G4 glycodendrimers in the same con-
ditions as those in which the induction was demonstrated pre-
viously. This indicates that the induction signal is indeed me-
diated by the NF-κB pathway.
We set out on a preliminary study of physiological rele-
vance of the immunomodulatory potential of PPI-m DS G4
glycodendrimer interference with the NF-κB pathway. We
verified the impact of dendrimer treatment on the expression
of TNFα (a model pro-inflammatory cytokine induced by
NF-κB activation) and IL-4 (a regulatory cytokine which
should not be directly influenced by NF-κB activation in my-
eloid cells). At the level of mRNA expression, verified by real-
time RT-PCR, the highest concentration of PPI-m DS G4
(100 μM) significantly induced the expression of the TNF
gene, while no impact on the expression of the IL4 gene was
detected (Fig. 6a). On the other hand, levels of both secreted
cytokines, measured at the protein level by ELISA in cellular
supernatants, were not influenced by glycodendrimer
treatment (Fig. 6b).
DISCUSSION
The identification and understanding of molecular mecha-
nisms by which dendritic nanostructures can change the cel-
lular environment provide valuable guidance for strategies
using these particles clinically, e.g. as carriers of bioactive com-
pounds (25) or as diagnostic contrast agents (26). The success-
ful use of dendrimers in living systems relies on their biocom-
patibility, which encompasses their impact on intrinsic
homeostasis of the organism and cell. Dendrimers have im-
portant features such as low cytoxicity (27), selective capacity
to deliver active compounds (28) and degradability in living
systems (29). These features are dependent mainly on specific
surface composition, including charge (30).
Glycodendrimers, which first appeared in the literature
in 1993 (31), are one of the most promising class of
dendrimers. They include biologically relevant carbohy-
drate, oligosaccharide or glycopeptide ligands at the pe-
riphery of dendritic scaffolds (PEI - poly(ethylene imine),
PAMAM - poly(amidoamine), PPI - poly(propylene imine)
and others), making them accessible for binding interac-
tions with multiple biomolecules (32). For example, it has
been reported that dendrimers with surface carbohydrate
ligands are successfully recognized by lectin receptors in
biological systems. A mannose moiety conjugated to the
amine terminals of PPI dendrimers was capable of
interacting with lectin receptors and become internalized
by macrophages (33) and undergo receptor-mediated en-
docytosis, which provides a mechanism for the selective
uptake of specific nanoparticles (34). Thus, immune
system-targeted sugar-modified dendrimers are an excit-
ing avenue of research not only in terms of delivering
drugs or antigens, but also with regard to direct impact
of dendrimers on immune system function and regulation.
Use of glycodendrimers combines the advantages of
Fig. 1 Effect of PPI-m DS G4
dendrimers on the viability of THP-
1 cells. Viability was determined by
the resazurin assay after 24 h (empty
symbols) and 72 h (filled symbols) of
treatment with dendrimers. Data
presented as percentage of viability
of control (untreated) cells, average
± S.E.M., n=4.
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carbohydrate modification for receptor interactions and
nanoparticle form for stability, uniformity and defined
pharmacokinetics.
In our previous studies, we have concentrated on novel
properties of maltose-modified glycodendrimers. They were
tested as potential drug delivery agents for nucleotides in ovar-
ian carcinoma cells and liver hepatocellular cells (19).
Polyplexes consisting of DNA and PEI with openmaltose shell
were shown to undergo simultaneously clathrin-dependent
and clathrin-independent endocytic processes in ovarian car-
cinoma cells (35). In PPI dendrimers of the fourth generation,
the extent of maltose modification (open shell, with positive
charge, or dense shell, with close to neutral charge) had a very
strong impact on their cytotoxicity, internalization pathways,
intracellular trafficking and distribution in primary and
metastatic melanoma cell lines (36). Similarly, PPI-m OS
and DS dendrimers differed in cytotoxicity profiles in
Chinese hamster ovary and human ovarian carcinoma cells
(13) and in their ability to cross blood–brain barrier (12).
In the present study, we used dense shell maltose-modified
4th generation poly(propylene imine) glycodendrimers (PPI-m
DSG4), which were previously shown to be significantly more
biocompatible (less cytotoxic) that the open shell variant, to
verify their potential immunomodulatory function in model
cells of the myeloid lineage – the human monocytic cell line
THP-1. We wanted to identify and understand potential mo-
lecular mechanisms by which glycodendrimers can influence
the cellular environment in a non-toxic manner. Thus, we
Fig. 2 Panel (a) and panel (b)
show the effect of PPI-m DS G3 or
PPI-m DS G4 dendrimers,
respectively, on mRNA expression
of IGFBP3 and TNFAIP3 marker
genes in THP-1 cells. Gene
expression was determined by
real-time RT-PCR after 24 h of
treatment with dendrimers. Data
presented as percentage of cognate
mRNA expression in control
(untreated) cells (number of
cognate mRNA copies per 1 copy
of geometric-averaged mRNA for
reference genes), average±
S.E.M., n=6.
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chose the THP-1 cell line since its signaling pathways are well
characterized and they are commonly used as models for
monocytes or non-activated macrophages. We used non-
differentiated THP-1 cells because their responses are more
general and do not depend on upregulated receptors (37).










































Fig. 4 Effect of PPI-m DS G4
dendrimers on DNA-binding
activity of nuclear NF-κB in THP-1
cells. Binding of NF-κB to a
consensus DNA probe was
determined by EMSA (nuclear
extract incubated with IRDye 700-
labelled probe, imaging on Odyssey
IR imager) after 2.5 h of treatment
with dendrimers. Treatment with
100 ng/ml of TNFα was used as
positive control of NF-κB activation.
Panel (a) shows a representative
EMSA image – the upper shifted
band corresponds to specific NF-κB
binding, the stronger lower shifted
band corresponds to a known non-
specific protein interacting with the
consensus sequence. The lanes in
the image correspond to: A, D –
untreated cells, B, E – PPI-m DS
100 μM, C, F – TNFα 100 ng/ml;
A, B, C – no probe competition; D,
E, F – 100× excess of unlabelled
probe. Panel (b) shows
quantification (by computer image
analysis using ImageJ software) of
the specific NF-κB-bound band.
Data presented as percentage of
band intensity in control (untreated)

























Fig. 3 Effect of PPI-m DS G4
dendrimers on nuclear translocation
of NF-κB in THP-1 cells. Subcellular
localisation of NF-κB was
determined by high-content
screening (immunofluorescence
with anti-p65 antibody and
automated microscopy/image
analysis) after 2.5 h of treatment
with dendrimers. Treatment with
100 ng/ml TNFα was used as
positive control of NF-κB nuclear
translocation. Data presented as
percentage of nuclear to
cytoplasmic staining ratio in control
(untreated) cells, average± S.E.M.,
n=6.
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the innate immune response, expressing i.a. lectin receptors,
which function as pattern recognition receptors for pathogens
(38), we postulated that maltose-modified glycodendrimers
may interact with signaling pathways important for cellular
function and in that manner potentially exert an immuno-
modulatory effect.
Because our main purpose was to identify novel immune-
related bioactivities of fully maltose-modified dendrimers, we
have not included unmodified (or partially-modified, so-called
open shell) PPI dendrimers in our study. These dendrimer
species were previously demonstrated to be strongly cytotoxic,
precluding their application in cellular exposure at concentra-
tions used in this study (12). Moreover, the presence of amino
groups on the surface of unmodified or partially modified
particles conveys a high affinity for nucleic acids (8), making
it impossible to efficiently isolate cellular RNA in their pres-
ence for quantitative RT-PCR.
Our results show that PPI-m DS G4 dendrimers indeed
activate the NF-κB signaling pathway, which is one of the
most important pathways for innate immunity. We demon-
strated this effect at several levels: in our experiments, the
tested glycodendrimers induced NF-κB nuclear translocation,
specific DNA binding activity, activated the transcription of
marker genes known to be specific NF-κB targets (IGFBP3 and
TNFAIP3), as well as of the TNF gene encoding TNFα, a
prototypic pro-inflammatory cytokine regulated by NF-κB.
These effects were exerted in a dose-dependent manner and
dendrimers had similar potency in all applied assays, demon-
strating a common molecular mechanism. It is important to
observe that the influence of PPI-m DS G4 treatment on
THP-1 cells was seen at relatively high dendrimer concentra-
tions (25–100 μM), which is significantly higher than concen-
trations previously tested for drug delivery applications
(12,13). Still, at these concentrations no deleterious effect on
cellular viability and growth could be seen even after 72 h of
incubation. Moreover, even at these high concentrations PPI-
m DS G4 had no effect on the expression levels of marker
genes, which are sensitive to even slight variations in activity
of other signaling pathways important for cellular function
and innate immunity (Jak/STAT, Keap1/Nrf2 and ER
stress). This means that these glycodendrimers do not cause
a generalized cellular stress (such as oxidative stress or
unfolded protein response, both of which are also known to
induce NF-κB activity) and their impact on NF-κB activity is
specific, potentially receptor-mediated. Thus, the main take-
home message from our study is that if maltose-modified
dendrimers are to be used at low concentrations for clinical
goals such as drug delivery, they should be fully bioorthogonal
for the innate immune system; if, on the other hand, they need
to be applied at relatively high concentrations, their immuno-
modulatory potential has to be taken into account despite the
generally high biocompatibility they otherwise demonstrate.
It is interesting to note that application of lower-generation
(G3) glycodendrimers, which were otherwise chemically
equivalent to the PPI-m DS G4 particles used in the rest of
the study, did not yield a significant stimulation of NF-κB
activity in the gene expression part of the study. The biocom-
patibility of the smaller nanoparticles has previously been
comprehensively described and found to be analogous to the
G4 variant (12). Two potential explanations for this advantage
of 4th generation glycodendrimers may be proposed: lower
dendrimer size may be inconvenient for direct interactions
with monocyte pattern recognition receptors on the surface
of THP-1 cells, especially if dendrimer internalization (e.g. by
phagocytosis) plays a role in this recognition. Alternatively, the
carbohydrate load of the smaller molecules (since the whole
surface is uniformly modified with maltose molecules, one
generation difference in size translates to a 2-fold difference
Fig. 5 Effect of NF-κB inhibitor
parthenolide on the induction of
mRNA expression of IGFBP3 and
TNFAIP3 marker genes by PPI-m
DS G4 dendrimers in THP-1 cells.
Gene expression was determined
by real-time RT-PCR after 24 h of
treatment with 5 μM parthenolide
and dendrimers. Data presented as
percentage of cognate mRNA
expression in control (untreated
with dendrimers or parthenolide)
cells (number of cognate mRNA
copies per 1 copy of geometric-
averaged mRNA for reference
genes), average± S.E.M., n=4.
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in the amount of surface-accessible moieties) may not be
enough to trigger a relevant signaling response.
It is important to note that activation of the NF-κB path-
way by even the highest dendrimer concentrations tested was
still significantly weaker than activation by TNFα, a cognate
ligand for a receptor known to strongly activate the NF-κB
pathway and to contribute to the inflammatory response.
Moreover, while the top concentration (100 μM) of PPI-m
DS G4 did activate TNFα expression at the mRNA level
(TNFα is both a target and an activator of the NF-κB path-
way), no corresponding increase in active cytokine secretion
from the cells was seen at the protein level. This is expected for
a specific and limited NF-κB activation event, since TNFα
secretion from the cell is a complex process regulated at sev-
eral NF-κB-independent stages (39). Therefore, the potential
effect of PPI-m DS G4 on the immune system in vivo would
most probably not involve full-scale inflammation and would
not be per se deleterious for the organism. The potential effect
of modest NF-κB activation is rather an adjuvant-like effect,
which may be very advantageous in dendrimer application for
treatment of tumors. Potentially, these nanoparticles can be
successfully used not only as vectors of targeted delivery of
drugs to cancer cells, but also as stimulants to augment the
anti-tumor attack of the innate immune system. This mild
adjuvant-like effect of glycodendrimers was previously men-
tioned in the study on their use in facilitating anti-tumor vac-
cine application, but no molecular mechanism was proposed
(40).
It is interesting to speculate on the nature and specificity of
interactions between maltose moieties on the PPI-m
Fig. 6 Effect of PPI-m DS G4
dendrimers on mRNA and protein
expression of cytokines in THP-1
cells. Panel (a) gene expression at
the mRNA level was determined
for TNF and IL4 genes by real-time
RT-PCR after 24 h of treatment
with dendrimers. Data presented as
percentage of cognate mRNA
expression in control (untreated)
cells (number of cognate mRNA
copies per 1 copy of geometric-
averaged mRNA for reference
genes), average± S.E.M., n=3.
Panel (b) gene expression at the
protein level was determined for
TNFα and IL-4 by ELISA in cellular
supernatants after 24 h of treatment
with dendrimers. Data presented as
percentage of cytokine levels in
supernatants form control
(untreated) cells, average± S.E.M.,
n=3.
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glycodendrimers and receptors on THP-1 cells. Monocytic
cells express a number of lectin-type receptors active in innate
immunity, and most of them can activate the NF-κB pathway
upon ligand binding – however, their cognate ligands are
usually saccharides which constitute pathogen-associated mo-
lecular patterns, such as mannose, trehalose or beta-glycan.
However, their is a growing body of research showing that
other simple oligosaccharides, even common food compo-
nents such as maltose, may interact with these receptors when
at high concentrations and/or in a locally dense molecular
conformation (as is the case with our glycodendrimers).
Human dectin-1 (macrophage beta-glucan receptor) has been
shown to bind to maltose-agarose with a similar avidity as to
mannan-agarose or chitin (41). Mincle, the macrophage tre-
halose receptor, binds to maltose-Sepharose to a significant
extent, although less tightly than to trehalose-Sepharose (42).
Also for the main soluble immune lectin, mannan-binding
lectin (MBL), it was shown that high concentrations of glucose
and short alpha-glucans can competitively displace its cognate
ligands (43). Since THP-1 express both dectin-1 and mincle,
and our experiments were performed in the presence of bo-
vine serum (containing MBL), any of these molecules may
have participated in the observed NF-κB activation.
Thus, our study confirms the overall high biocompatibility
of maltose-modified (G4) glycodendrimers in a novel cellular
system (myeloid cell line). On the other hand, it provides for
the first time a mechanistic basis for potential additional bio-
logical effects of their application, specifically by modulating
the innate immune system via activation of the NF-κB path-
way. This side effect has to be taken into account in any po-
tential clinical application, but is not necessarily a negative
effect – the immunostimulatory potency may be a boon for
dendrimers used in anticancer or antiviral settings. Further
studies are needed on the specific cellular receptors responsi-
ble for interaction with glycodendrimers, especially since car-
bohydrate ligands are known to trigger immune response in
many cases, so a role of the maltose moiety can be postulated.
Our study demonstrates comprehensively that it is very im-
portant to study novel nanoparticles with potential clinical
applications not only for their expected activity, but also for
collateral actions and their molecular mechanism.
CONCLUSIONS
Maltose-modified PPI G4 dendrimers are highly promising
glyconanoparticles in view of the drastic increase in biocom-
patibility in comparison to their unmodified congeners.
However, for any clinical application, a careful examination
of even slight interference with normal homeostasis must be
studied at the molecular level, as exemplified by our finding
that PPI-m G4 dendrimers in the fully modified (dense shell)
variant induce the activity of the NF-κB pathway in a cellular
model of monocytes – classical effectors of innate immunity.
Our results lead to the direct conclusion that exposure to high
concentrations of PPI-m DS G4 enhances the transcriptional
activity of NF-κB, leading to a moderate induction of expres-
sion of genes controlled by this pathway. This induction is
incommensurate with strong activation seen upon pro-
inflammatory stimulation and does not itself lead to an in-
crease in secretion of pro-inflammatory cytokines by cells.
However, in view of the delicate signalling homeostasis in
myeloid cells and potential cross-talk mechanisms with other
immunomodulatory stimuli, this is a significant finding that
leads both to potential avenues of in vivo research into dendri-
mer application as clinical agents (e.g. adjuvants) and to ca-
veats for systemic dendrimer use as theoretical ly
bioorthogonal drug delivery vehicles.
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